YAP1 and ovarian carcinoma: HNK-induced apoptosis and tumor growth inhibition in vivo were reversed by the YAP agonist XMU-MP-1, underscoring the centrality of the YAP/TAZ pathway in ovarian cancer progression and HNK's therapeutic potential (Liu et al., 2024[74]).